Sodium chlorite, [w:] GESTIS-Stoffdatenbank [online], Institut für Arbeitsschutz der Deutschen Gesetzlichen Unfallversicherung, ZVG: 1630 [dostęp 2017-02-02](niem. • ang.).
doi.org
dx.doi.org
HelmutH.VogtHelmutH. i inni, Chlorine Oxides and Chlorine Oxygen Acids, [w:] Ullmann’s Encyclopedia of Industrial Chemistry, Weinheim: Wiley‐VCH, 2000, s. 19–20, DOI: 10.1002/14356007.a06_483(ang.).
Hans UlrichH.U.SüssHans UlrichH.U., Bleaching, [w:] Ullmann’s Encyclopedia of Industrial Chemistry, Weinheim: Wiley‐VCH, 2006, DOI: 10.1002/14356007.a04_191.pub2(ang.).
KlausK.FischerKlausK. i inni, Textile Auxiliaries, [w:] Ullmann’s Encyclopedia of Industrial Chemistry, Weinheim: Wiley‐VCH, 2000, s. 33, 36, DOI: 10.1002/14356007.a26_227(ang.).
AlfredA.ThomasAlfredA., Fats and Fatty Oils, [w:] Ullmann’s Encyclopedia of Industrial Chemistry, Weinheim: Wiley‐VCH, 2000, s. 32, DOI: 10.1002/14356007.a10_173(ang.).
Robert G.R.G.MillerRobert G.R.G. i inni, Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS, „Neurology – Neuroimmunology & Neuroinflammation”, 2 (3), 2015, s. e100, DOI: 10.1212/NXI.0000000000000100, PMID: 25884010, PMCID: PMC4396529.
Robert G.R.G.MillerRobert G.R.G. i inni, NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study, „Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration”, 15 (7–8), 2014, s. 601–609, DOI: 10.3109/21678421.2014.951940, PMID: 25192333, PMCID: PMC5524125.
Syed I.S.I.KhalidSyed I.S.I. i inni, Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials, „Front Neurol”, 8, 2017, s. 486, DOI: 10.3389/fneur.2017.00486.
ALSUntangled No. 19: Sodium chlorite, „Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration”, 14 (3), 2013, s. 236–238, DOI: 10.3109/21678421.2013.769718(ang.).
John Ming RenJ.M.R.LohJohn Ming RenJ.M.R., HumairaH.ShafiHumairaH., Kikuchi-Fujimoto disease presenting after consumption of ‘Miracle Mineral Solution’ (sodium chlorite), „BMJ Case Rep”, 2014, DOI: 10.1136/bcr-2014-205832, PMID: 25422331, PMCID: PMC4244351(ang.).
Sodium chlorite, [w:] Community register of orphan medicinal products [online], Directorate General Health & Consumers, European Commission [dostęp 2018-01-27](ang.).
fda.gov
accessdata.fda.gov
Sodium chlorite, [w:] Orphan Drug Designations and Approvals [online], U.S. Food and Drug Administration [dostęp 2018-01-27](ang.).
Robert G.R.G.MillerRobert G.R.G. i inni, Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS, „Neurology – Neuroimmunology & Neuroinflammation”, 2 (3), 2015, s. e100, DOI: 10.1212/NXI.0000000000000100, PMID: 25884010, PMCID: PMC4396529.
Robert G.R.G.MillerRobert G.R.G. i inni, NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study, „Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration”, 15 (7–8), 2014, s. 601–609, DOI: 10.3109/21678421.2014.951940, PMID: 25192333, PMCID: PMC5524125.
John Ming RenJ.M.R.LohJohn Ming RenJ.M.R., HumairaH.ShafiHumairaH., Kikuchi-Fujimoto disease presenting after consumption of ‘Miracle Mineral Solution’ (sodium chlorite), „BMJ Case Rep”, 2014, DOI: 10.1136/bcr-2014-205832, PMID: 25422331, PMCID: PMC4244351(ang.).